Health News
FDA Approves Nexavar for Advanced Thyroid Cancer
Thankfully, m ost thyroid cancers are treatable. However, when thyroid cancer comes back after treatment or spreads to other areas of the body, the disease is harder to treat.
FDA Approves Nexavar to Treat Type of Thyroid Cancer
The U.S. Food and Drug Administration today expanded the approved uses of Nexavar (sorafenib) to treat late-stage (metastatic) differentiated thyroid cancer.
Two New Weapons Against Thyroid Cancer
There hasn’t been much progress in the treatment of advanced thyroid cancer over the last 40 years. And there are really no treatment options for thyroid cancer involving the mutated gene called BRAF. Two new weapons offer good news on both fronts.
Nexavar Gets FDA Nod for Thyroid Cancer
Most thyroid cancers are treatable, even curable. However, as with most cancers, once spreading (metastasis) begins, tumors are more difficult to treat. A medication is being evaluated to strengthen the arsenal against advanced thyroid cancer.
New Rx for Thyroid Cancer
Thyroid cancers are typically (and thankfully) less aggressive than most other cancers but sometimes they cannot be treated using traditional therapy.
Phase 3 DECISION Trial of Nexavar (sorafenib) Meets Primary Endpoint
Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. today announced that a Phase 3 trial of Nexavar® (sorafenib) tablets in patients with locally advanced or metastatic radioactive iodine-refractory (RAI) differentiated thyroid cancer has met its primary endpoint of a statistically significant improvement of progression-free survival.